A citation-based method for searching scientific literature

Mathieu Chevallier, Maxime Borgeaud, Alfredo Addeo, Alex Friedlaender. World J Clin Oncol 2021
Times Cited: 9







List of co-cited articles
3 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
Jude Canon, Karen Rex, Anne Y Saiki, Christopher Mohr, Keegan Cooke, Dhanashri Bagal, Kevin Gaida, Tyler Holt, Charles G Knutson, Neelima Koppada,[...]. Nature 2019
652
22

EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics.
Daniel M Freed, Nicholas J Bessman, Anatoly Kiyatkin, Emanuel Salazar-Cavazos, Patrick O Byrne, Jason O Moore, Christopher C Valley, Kathryn M Ferguson, Daniel J Leahy, Diane S Lidke,[...]. Cell 2017
137
22

Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 (Her2) Driver Mutations.
Joshua R Veatch, Brenda L Jesernig, Julia Kargl, Matthew Fitzgibbon, Sylvia M Lee, Christina Baik, Renato Martins, A McGarry Houghton, Stanley R Riddell. Cancer Immunol Res 2019
41
11

Interplay between heat shock proteins, inflammation and cancer: a potential cancer therapeutic target.
Paul C Ikwegbue, Priscilla Masamba, Londiwe S Mbatha, Babatunji E Oyinloye, Abidemi P Kappo. Am J Cancer Res 2019
9
11

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
11

Fibrinogen is associated with EGFR mutation status and lymphatic metastasis in non-small cell lung cancer.
Jian Guan, Nan Xiao, Chun Qiu, Qin Li, Min Chen, Yao Zhang, Yong Dai, Lu Li, Yue Zhang, Mi Yang,[...]. Oncol Lett 2019
5
20


Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
Neal I Lindeman, Philip T Cagle, Mary Beth Beasley, Dhananjay Arun Chitale, Sanja Dacic, Giuseppe Giaccone, Robert Brian Jenkins, David J Kwiatkowski, Juan-Sebastian Saldivar, Jeremy Squire,[...]. J Thorac Oncol 2013
566
11

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
11

Chronic inflammation towards cancer incidence: A systematic review and meta-analysis of epidemiological studies.
Nathalie Michels, Carola van Aart, Jens Morisse, Amy Mullee, Inge Huybrechts. Crit Rev Oncol Hematol 2021
18
11

Inflammation scores as prognostic biomarkers in small cell lung cancer: a systematic review and meta-analysis.
Anne Winther-Larsen, Ninna Aggerholm-Pedersen, Birgitte Sandfeld-Paulsen. Syst Rev 2021
5
20

Cancer-related inflammation.
Alberto Mantovani, Paola Allavena, Antonio Sica, Frances Balkwill. Nature 2008
11

Combining Carcinoembryonic Antigen and Platelet to Lymphocyte Ratio to Predict Brain Metastasis of Resected Lung Adenocarcinoma Patients.
Wei Wang, Chao Bian, Di Xia, Jin-Xi He, Ping Hai, Ren Zhao, Yan-Yang Wang. Biomed Res Int 2017
12
11

Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non-small cell lung cancer.
Yujiao Xie, Yi Zhang, Lutao Du, Xiumei Jiang, Suzhen Yan, Weili Duan, Juan Li, Yao Zhan, Lili Wang, Shujun Zhang,[...]. Mol Oncol 2018
80
11

Impacts of post-radiotherapy lymphocyte count on progression-free and overall survival in patients with stage III lung cancer.
Juliana Matiello, Alan Dal Pra, Laise Zardo, Ricardo Silva, Danilo C Berton. Thorac Cancer 2020
4
25

Pretreatment plasma fibrinogen level as a prognostic biomarker for patients with lung cancer.
Yi Zhang, Junyan Cao, Yinan Deng, Yiming Huang, Rong Li, Guozhen Lin, Min Dong, Zenan Huang. Clinics (Sao Paulo) 2020
9
11

The impact of the preoperative peripheral lymphocyte count and lymphocyte percentage in patients with colorectal cancer.
Yasuhito Iseki, Masatsune Shibutani, Kiyoshi Maeda, Hisashi Nagahara, Tatsuro Tamura, Go Ohira, Sadaaki Yamazoe, Kenjiro Kimura, Takahiro Toyokawa, Ryosuke Amano,[...]. Surg Today 2017
27
11

Targeting lung cancer screening to individuals at greatest risk: the role of genetic factors.
Mikey B Lebrett, Emma J Crosbie, Miriam J Smith, Emma R Woodward, D Gareth Evans, Philip A J Crosbie. J Med Genet 2021
3
33

Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment.
Norbaini Binti Abdol Razak, Gabrielle Jones, Mayank Bhandari, Michael C Berndt, Pat Metharom. Cancers (Basel) 2018
149
11

The role of fibrinogen, fibrin and fibrin(ogen) degradation products (FDPs) in tumor progression.
Joanna Kołodziejczyk, Michał B Ponczek. Contemp Oncol (Pozn) 2013
31
11


Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: A systematic review and meta-analysis.
C Perisanidis, A Psyrri, E E Cohen, J Engelmann, G Heinze, B Perisanidis, A Stift, M Filipits, G Kornek, E Nkenke. Cancer Treat Rev 2015
100
11

Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients.
Xiaobin Gu, Shaoqian Sun, Xian-Shu Gao, Wei Xiong, Shangbin Qin, Xin Qi, Mingwei Ma, Xiaoying Li, Dong Zhou, Wen Wang,[...]. Sci Rep 2016
59
11

Elevated pretreatment platelet-to-lymphocyte ratio is associated with poor survival in stage IV non-small cell lung cancer with malignant pleural effusion.
Jeong Uk Lim, Chang Dong Yeo, Hye Seon Kang, Chan Kwon Park, Ju Sang Kim, Jin Woo Kim, Seung Joon Kim, Sang Haak Lee. Sci Rep 2019
11
11

Platelets and fibrinogen facilitate each other in protecting tumor cells from natural killer cytotoxicity.
Sheng Zheng, Jian Shen, Yang Jiao, Yan Liu, Chunmei Zhang, Min Wei, Shui Hao, Xianlu Zeng. Cancer Sci 2009
106
11

New revisions and current issues in the eighth edition of the TNM classification for non-small cell lung cancer.
Aritoshi Hattori, Kazuya Takamochi, Shiaki Oh, Kenji Suzuki. Jpn J Clin Oncol 2019
22
11

Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.
Konstantinos Syrigos, Dimitra Grapsa, Rabiatou Sangare, Ilias Evmorfiadis, Annette K Larsen, Patrick Van Dreden, Paraskevi Boura, Andriani Charpidou, Elias Kotteas, Theodoros N Sergentanis,[...]. Oncologist 2018
18
11

Prognostic significance of neutrophil-lymphocyteratio/platelet-lymphocyteratioin lung cancers: a meta-analysis.
Hong-Bo Yang, Meng Xing, Lei-Na Ma, Ling-Xin Feng, Zhuang Yu. Oncotarget 2016
36
11

Inflammation and cancer: back to Virchow?
F Balkwill, A Mantovani. Lancet 2001
11

Neutrophil-Lymphocyte Ratio as a Prognostic Marker for Lung Adenocarcinoma After Complete Resection.
Yusuke Takahashi, Masafumi Kawamura, Tai Hato, Masahiko Harada, Noriyuki Matsutani, Hirotoshi Horio. World J Surg 2016
26
11

Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
Si-Yang Liu, Zhong-Yi Dong, Si-Pei Wu, Zhi Xie, Li-Xu Yan, Yu-Fa Li, Hong-Hong Yan, Jian Su, Jin-Ji Yang, Qing Zhou,[...]. Lung Cancer 2018
35
11

Serum amyloid A binds to fibrin(ogen), promoting fibrin amyloid formation.
Martin J Page, Greig J A Thomson, J Massimo Nunes, Anna-Mart Engelbrecht, Theo A Nell, Willem J S de Villiers, Maria C de Beer, Lize Engelbrecht, Douglas B Kell, Etheresia Pretorius. Sci Rep 2019
34
11

Aberrant Factors of Fibrinolysis and Coagulation in Pancreatic Cancer.
Lianghua Fang, Qing Xu, Jun Qian, Jin-Yong Zhou. Onco Targets Ther 2021
1
100

Prognostic role of preoperative platelet, fibrinogen, and D-dimer levels in patients with non-small cell lung cancer: A multicenter prospective study.
Can Hou, Feng Jiang, Haitao Ma, Quan Zhu, Zhonglin Wang, Biao Zhao, Tao Xue, Sheng Tan, Rusong Yang, Yongxiang Qian,[...]. Thorac Cancer 2019
17
11

Objective measurement and clinical significance of TILs in non-small cell lung cancer.
Kurt A Schalper, Jason Brown, Daniel Carvajal-Hausdorf, Joseph McLaughlin, Vamsidhar Velcheti, Konstantinos N Syrigos, Roy S Herbst, David L Rimm. J Natl Cancer Inst 2015
228
11

Albumin-to-fibrinogen ratio as a promising biomarker to predict clinical outcome of non-small cell lung cancer individuals.
Shu-Qi Li, Yu-Huan Jiang, Jin Lin, Jing Zhang, Fan Sun, Qiu-Fang Gao, Lei Zhang, Qing-Gen Chen, Xiao-Zhong Wang, Hou-Qun Ying. Cancer Med 2018
54
11

Fibrinogen as a key regulator of inflammation in disease.
Dimitrios Davalos, Katerina Akassoglou. Semin Immunopathol 2012
479
11

Inflammation and cancer: advances and new agents.
Shanthini M Crusz, Frances R Balkwill. Nat Rev Clin Oncol 2015
552
11


Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice.
Joseph S Palumbo, Jill M Potter, Lisa S Kaplan, Kathryn Talmage, David G Jackson, Jay L Degen. Cancer Res 2002
200
11

Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells.
J S Palumbo, K W Kombrinck, A F Drew, T S Grimes, J H Kiser, J L Degen, T H Bugge. Blood 2000
425
11


The biology and management of non-small cell lung cancer.
Roy S Herbst, Daniel Morgensztern, Chris Boshoff. Nature 2018
11

Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs.
Sara A Hurvitz, Joyce O'Shaughnessy, Ginny Mason, Denise A Yardley, Mohammad Jahanzeb, Adam Brufsky, Hope S Rugo, Sandra M Swain, Peter A Kaufman, Debu Tripathy,[...]. Clin Cancer Res 2019
28
11

Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
Reatul Karim, Claudio Palazzo, Brigitte Evrard, Geraldine Piel. J Control Release 2016
129
11

Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target.
Guo Chen, Nitin Chakravarti, Kimberly Aardalen, Alexander J Lazar, Michael T Tetzlaff, Bradley Wubbenhorst, Sang-Bae Kim, Scott Kopetz, Alicia A Ledoux, Y N Vashisht Gopal,[...]. Clin Cancer Res 2014
101
11

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell,[...]. N Engl J Med 2017
11

Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases.
Pascale Tomasini, Julie Egea, Maxime Souquet-Bressand, Laurent Greillier, Fabrice Barlesi. Ther Adv Respir Dis 2019
16
11

Scientific Advances in Lung Cancer 2015.
Anne S Tsao, Giorgio V Scagliotti, Paul A Bunn, David P Carbone, Graham W Warren, Chunxue Bai, Harry J de Koning, A Uraujh Yousaf-Khan, Annette McWilliams, Ming Sound Tsao,[...]. J Thorac Oncol 2016
158
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.